TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03887273: Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

Sponsor: Q Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$4,317,660

Rescue Site Savings

+$2,850,220

Unlock Full NCT03887273 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03887273 Rescue Dossier →